| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
127,390,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases. Co.'s existing pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus, influenza A virus, and human immunodeficiency virus. Co. has collaborate with Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A. to focus on treating and preventing severe acute respiratory syndrome coronavirus 2 (the virus that causes COVID-19 illness). Co. is developing differentiated monoclonal antibodies, like sotrovimab and VIR-7832, as well as vaccines and small molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
10,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$246,341 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
4 |
| Total Shares Sold |
136,328 |
167,399 |
782,068 |
6,005,613 |
| Total Sell Value |
$1,354,144 |
$1,671,921 |
$17,840,473 |
$153,953,368 |
| Total People Sold |
5 |
5 |
9 |
11 |
| Total Sell Transactions |
7 |
10 |
24 |
123 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-11-16 |
4 |
OE |
$1.53 |
$2,104 |
D/D |
1,375 |
109,075 |
|
- |
|
| Pang Phillip |
Chief Medical Officer |
• – – |
2021-11-03 |
4 |
AS |
$36.47 |
$182,331 |
D/D |
(5,000) |
100,277 |
|
- |
|
| Pang Phillip |
Chief Medical Officer |
• – – |
2021-11-03 |
4 |
OE |
$5.18 |
$25,875 |
D/D |
5,000 |
105,277 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-11-02 |
4 |
AS |
$36.94 |
$50,793 |
D/D |
(1,375) |
107,700 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-11-02 |
4 |
OE |
$1.53 |
$2,104 |
D/D |
1,375 |
109,075 |
|
- |
|
| Pang Phillip |
Chief Medical Officer |
• – – |
2021-10-20 |
4 |
AS |
$39.65 |
$158,596 |
D/D |
(4,000) |
100,277 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-10-19 |
4 |
AS |
$38.87 |
$53,446 |
D/D |
(1,375) |
107,700 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-10-19 |
4 |
OE |
$1.53 |
$2,104 |
D/D |
1,375 |
109,075 |
|
- |
|
| Sato Vicki L |
Director |
– • – |
2021-10-19 |
4 |
AS |
$39.12 |
$600,314 |
D/D |
(15,174) |
1,581,440 |
|
- |
|
| Pang Phillip |
Chief Medical Officer |
• – – |
2021-10-06 |
4 |
AS |
$34.56 |
$172,781 |
D/D |
(5,000) |
104,277 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-10-05 |
4 |
AS |
$33.75 |
$46,406 |
D/D |
(1,375) |
107,700 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-10-05 |
4 |
OE |
$1.53 |
$2,104 |
D/D |
1,375 |
109,075 |
|
- |
|
| Pang Phillip |
Chief Medical Officer |
• – – |
2021-09-27 |
4 |
OE |
$0.86 |
$4,275 |
D/D |
5,000 |
109,277 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-09-22 |
4 |
OE |
$1.53 |
$12,240 |
D/D |
8,000 |
107,700 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-09-21 |
4 |
AS |
$50.00 |
$206,250 |
D/D |
(4,125) |
99,700 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-09-21 |
4 |
OE |
$1.53 |
$6,311 |
D/D |
4,125 |
103,825 |
|
- |
|
| Sato Vicki L |
Director |
– • – |
2021-09-17 |
4 |
AS |
$52.31 |
$796,301 |
D/D |
(15,174) |
1,596,614 |
|
- |
|
| Pang Phillip |
Chief Medical Officer |
• – – |
2021-09-15 |
4 |
AS |
$49.58 |
$248,462 |
D/D |
(5,000) |
104,277 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-09-07 |
4 |
AS |
$49.00 |
$204,875 |
D/D |
(4,125) |
99,700 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-09-07 |
4 |
OE |
$1.53 |
$6,311 |
D/D |
4,125 |
103,825 |
|
- |
|
| Pang Phillip |
Chief Medical Officer |
• – – |
2021-09-01 |
4 |
AS |
$48.72 |
$247,879 |
D/D |
(5,000) |
109,277 |
|
- |
|
| Pang Phillip |
Chief Medical Officer |
• – – |
2021-09-01 |
4 |
OE |
$1.53 |
$7,650 |
D/D |
5,000 |
114,277 |
|
- |
|
| Napolitano Janet |
Director |
– • – |
2021-08-30 |
4 |
AS |
$51.15 |
$73,400 |
D/D |
(1,435) |
3,374 |
|
- |
|
| Napolitano Janet |
Director |
– • – |
2021-08-30 |
4 |
OE |
$41.64 |
$59,753 |
D/D |
1,435 |
4,809 |
|
- |
|
| Virgin Herbert |
EVP, Research & CSO |
• – – |
2021-08-25 |
4 |
AS |
$50.00 |
$137,500 |
D/D |
(2,750) |
99,700 |
|
- |
|
575 Records found
|
|
Page 13 of 23 |
|
|
